查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606709

数位生物标记市场：按类型、治疗领域、应用划分 - 2025-2030 年全球预测

Digital Biomarkers Market by Type (Hardware, Software), Therapeutic Area (Cardiovascular and metabolic disorders (CVMD), Musculoskeletal disorders, Neurological disorders), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

数位生物标记市场2023年估值为36.3亿美元，预计到2024年将达到43.4亿美元，复合年增长率为19.97%，预计到2030年将达到130亿美元。

数位生物标记是指透过智慧型手机、穿戴式装置和其他远端感测器等数位装置收集和测量的可量化的生理、行为和身体资料。它透过提供持续、即时监控、实现个人化医疗和预防性健康管理，在医疗保健转型中发挥关键作用。对数位生物标记的需求源于其比传统方法更可靠、更具成本效益并提供全面见解的潜力。疾病诊断、治疗监测和健康管理的应用在製药、生物技术、医疗保健和学术研究等领域不断增加。主要最终用途包括慢性病管理、临床试验和心理健康评估，这些用途受益于增强的患者资料收集和改善的结果。

主要市场统计
基准年[2023] 36.3亿美元
预测年份 [2024] 43.4亿美元
预测年份 [2030] 130亿美元
复合年增长率（%） 19.97%

市场成长受到数位健康技术进步、慢性病盛行率上升以及对个人化医疗解决方案不断增长的需求的显着影响。此外，人工智慧和机器学习的兴起正在推动数位生物标记资料的创新分析并提供可行的见解。然而，市场扩张面临监管挑战、资料隐私问题以及广泛检验和标准化的需求等障碍。此外，与现有医疗保健系统的整合可能是一个营运挑战。

开发可互通的平台存在机会，该平台整合了各种数位生物标记，以实现一致的医疗保健策略，并强调互通性和安全性。公司可以利用与科技公司的伙伴关係来增强其资料分析能力，同时优先考虑改善用户体验以推动采用。创新领域包括提高感测器的准确性、降低数位设备的成本以及开拓新兴国家开拓的市场。此外，透过与学术机构的联合研究，我们可以引领新生物标记和应用的发展。持续创新和策略规划可以帮助公司驾驭复杂的数位生物标记环境，实现永续成长，并为全球医疗保健的进步做出有意义的贡献。

市场动态：揭示快速发展的数位生物标记市场的关键市场洞察

数位生物标记市场正在因供需的动态相互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 扩大生物标记测试在慢性病治疗的应用
    • 数位生物标记诊断的主要好处
    • 数位生物标记在以病人为中心的药物开发和精准医疗的应用
  • 市场限制因素
    • 生物标誌物开发和数位生物标记采用相关的高成本
  • 市场机会
    • 得益于数位生物标记的最新进展，灵活性和定製配置
    • 政府对远端医疗基础设施的投资
  • 市场挑战
    • 与资料检验和解释相关的问题

波特五力：驾驭数位生物标记市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解数位生物标记市场的外部影响

外部宏观环境因素在塑造数位生物标记市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解数位生物标记市场的竞争状况

数位生物标记市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵数位生物标记市场供应商的绩效评估

FPNV 定位矩阵是评估数位生物标记市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製数位生物标誌物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对数位生物标记市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 在慢性病治疗中增加生物标记检测的使用
      • 数位生物标记诊断的主要好处
      • 数位生物标记在以病人为中心的药物开发和精准医疗的应用
    • 抑制因素
      • 与生物标记物开发和数位生物标记物采用相关的高成本
    • 机会
      • 数位生物标记的最新进展实现了更灵活和客製化的配置
      • 政府对远端医疗基础设施的投资
    • 任务
      • 与资料检验和解释相关的问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章数位生物标记市场：按类型

  • 硬体
    • 感应器
    • 穿戴式装置
  • 软体

第七章依治疗领域分類的数位生物标记市场

  • 心血管和代谢疾病（CVMD）
  • 肌肉骨骼疾病
  • 神经系统疾病
  • 精神疾病
  • 呼吸系统疾病
  • 睡眠和运动障碍

第八章数位生物标记市场：依最终用途

  • 医疗保健消费者
  • 医疗服务提供方

第九章美洲数位生物标记市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区数位生物标记市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的数位生物标记市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • ActiGraph, LLC
  • Adherium
  • Akili, Inc.
  • Altoida, Inc.
  • Amgen Inc.
  • Aural Analytics, Inc.
  • Biofourmis Pte. Ltd.
  • Biogen Inc.
  • Brainomix
  • Chugai Pharmaceutical Co., Ltd.
  • Clarigent Health
  • Eli Lilly and Company
  • Empatica Inc.
  • F. Hoffmann-La Roche Ltd.
  • Feel Therapeutics
  • GERO PTE. LTD.
  • Huma Therapeutics Limited
  • IXICO PLC
  • Kinsa Inc.
  • Koneksa Health
  • Medable Inc.
  • Owkin, Inc.
  • Sidekick Health ehf.
  • Verily Life Sciences
  • VivoSense, Inc
Product Code: MRR-5C6F41F5AF45

The Digital Biomarkers Market was valued at USD 3.63 billion in 2023, expected to reach USD 4.34 billion in 2024, and is projected to grow at a CAGR of 19.97%, to USD 13.00 billion by 2030.

Digital biomarkers refer to quantifiable physiological, behavioral, and physical data collected and measured through digital devices like smartphones, wearables, and other remote sensors. They play a critical role in transforming healthcare by providing continuous and real-time monitoring, enabling personalized medicine and proactive health management. The necessity of digital biomarkers arises from their potential to offer more reliable, cost-effective, and comprehensive insights than traditional methods. They are increasingly applied in disease diagnosis, treatment monitoring, and health management across sectors such as pharmaceuticals, biotechnology, healthcare providers, and academic research. Key end-use applications involve chronic disease management, clinical trials, and mental health assessments, which benefit from enhanced patient data collection and improved outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 3.63 billion
Estimated Year [2024] USD 4.34 billion
Forecast Year [2030] USD 13.00 billion
CAGR (%) 19.97%

Market growth is significantly influenced by technological advancements in digital health, an increasing prevalence of chronic diseases, and a growing demand for personalized healthcare solutions. Furthermore, the rise of artificial intelligence and machine learning is driving innovative analytics of digital biomarker data, providing actionable insights. However, market expansion faces hurdles such as regulatory challenges, data privacy concerns, and the need for extensive validation and standardization. Additionally, integration with existing healthcare systems can pose operational challenges.

Opportunities exist in developing interoperable platforms that integrate various digital biomarkers into cohesive healthcare strategies, emphasizing interoperability and security. Businesses can capitalize on partnerships with technology companies to enhance data analytics capabilities, while prioritizing the enhancement of user experience to encourage adoption. Innovation areas include improving sensor accuracy, reducing costs of digital devices, and exploring untapped markets in emerging economies. Furthermore, leveraging collaborations with academic institutions for research can lead to the development of novel biomarkers and applications. With continuous innovation and strategic planning, companies can navigate the complex landscape of digital biomarkers to achieve sustainable growth and make meaningful contributions to global healthcare advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Digital Biomarkers Market

The Digital Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing usage of biomarkers testing for the treatment of chronic diseases
    • Significant benefits of digital biomarkers diagnosis
    • Applications of digital biomarkers in patient-focused drug development and precision medicine
  • Market Restraints
    • High cost associated with biomarkers development and adoption of digital biomarkers
  • Market Opportunities
    • Recent advancements in digital biomarkers for more flexibility and customized configuration
    • Government investment in telehealth infrastructure
  • Market Challenges
    • Issues associated with data validation and interpretation

Porter's Five Forces: A Strategic Tool for Navigating the Digital Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Digital Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Digital Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Digital Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Digital Biomarkers Market

A detailed market share analysis in the Digital Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Digital Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Digital Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Digital Biomarkers Market

A strategic analysis of the Digital Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Digital Biomarkers Market, highlighting leading vendors and their innovative profiles. These include ActiGraph, LLC, Adherium, Akili, Inc., Altoida, Inc., Amgen Inc., Aural Analytics, Inc., Biofourmis Pte. Ltd., Biogen Inc., Brainomix, Chugai Pharmaceutical Co., Ltd., Clarigent Health, Eli Lilly and Company, Empatica Inc., F. Hoffmann-La Roche Ltd., Feel Therapeutics, GERO PTE. LTD., Huma Therapeutics Limited, IXICO PLC, Kinsa Inc., Koneksa Health, Medable Inc., Owkin, Inc., Sidekick Health ehf., Verily Life Sciences, and VivoSense, Inc.

Market Segmentation & Coverage

This research report categorizes the Digital Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Hardware and Software. The Hardware is further studied across Sensor and Wearable Device.
  • Based on Therapeutic Area, market is studied across Cardiovascular and metabolic disorders (CVMD), Musculoskeletal disorders, Neurological disorders, Psychiatric Disorders, Respiratory Disorders, and Sleep & Movement Disease.
  • Based on End-Use, market is studied across Healthcare Consumers and Healthcare Providers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing usage of biomarkers testing for the treatment of chronic diseases
      • 5.1.1.2. Significant benefits of digital biomarkers diagnosis
      • 5.1.1.3. Applications of digital biomarkers in patient-focused drug development and precision medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with biomarkers development and adoption of digital biomarkers
    • 5.1.3. Opportunities
      • 5.1.3.1. Recent advancements in digital biomarkers for more flexibility and customized configuration
      • 5.1.3.2. Government investment in telehealth infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with data validation and interpretation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Digital Biomarkers Market, by Type

  • 6.1. Introduction
  • 6.2. Hardware
    • 6.2.1. Sensor
    • 6.2.2. Wearable Device
  • 6.3. Software

7. Digital Biomarkers Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Cardiovascular and metabolic disorders (CVMD)
  • 7.3. Musculoskeletal disorders
  • 7.4. Neurological disorders
  • 7.5. Psychiatric Disorders
  • 7.6. Respiratory Disorders
  • 7.7. Sleep & Movement Disease

8. Digital Biomarkers Market, by End-Use

  • 8.1. Introduction
  • 8.2. Healthcare Consumers
  • 8.3. Healthcare Providers

9. Americas Digital Biomarkers Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Digital Biomarkers Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Digital Biomarkers Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ActiGraph, LLC
  • 2. Adherium
  • 3. Akili, Inc.
  • 4. Altoida, Inc.
  • 5. Amgen Inc.
  • 6. Aural Analytics, Inc.
  • 7. Biofourmis Pte. Ltd.
  • 8. Biogen Inc.
  • 9. Brainomix
  • 10. Chugai Pharmaceutical Co., Ltd.
  • 11. Clarigent Health
  • 12. Eli Lilly and Company
  • 13. Empatica Inc.
  • 14. F. Hoffmann-La Roche Ltd.
  • 15. Feel Therapeutics
  • 16. GERO PTE. LTD.
  • 17. Huma Therapeutics Limited
  • 18. IXICO PLC
  • 19. Kinsa Inc.
  • 20. Koneksa Health
  • 21. Medable Inc.
  • 22. Owkin, Inc.
  • 23. Sidekick Health ehf.
  • 24. Verily Life Sciences
  • 25. VivoSense, Inc

LIST OF FIGURES

  • FIGURE 1. DIGITAL BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. DIGITAL BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DIGITAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DIGITAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIGITAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIGITAL BIOMARKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SENSOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLE DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOVASCULAR AND METABOLIC DISORDERS (CVMD), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SLEEP & MOVEMENT DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEALTHCARE CONSUMERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 191. DIGITAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. DIGITAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023